Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.65 USD
-0.39 (-1.50%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $25.67 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Beam Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -132.53 | -289.09 | -370.64 | -194.59 | -78.33 |
Depreciation/Amortization & Depletion | -9.73 | 4.74 | 7.38 | 4.85 | 2.58 |
Net Change from Assets/Liabilities | -114.44 | 236.16 | 121.24 | 73.48 | -3.40 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 107.50 | 70.72 | 175.75 | 20.51 | 7.14 |
Net Cash From Operating Activities | -149.20 | 22.53 | -66.27 | -95.74 | -72.00 |
Property & Equipment | -33.73 | -48.95 | -46.81 | -16.36 | -12.52 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.62 | 0.00 | 0.00 |
Investments | 105.57 | -412.39 | -247.95 | -83.77 | -54.14 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 71.84 | -461.34 | -294.14 | -100.12 | -66.66 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 279.33 | 114.07 | 767.08 | 3.16 | 38.09 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.88 | -2.48 | -10.93 | 319.17 | 3.19 |
Net Cash from Financing Activities | 276.45 | 111.59 | 756.14 | 322.32 | 41.28 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 199.09 | -327.22 | 395.73 | 126.46 | -97.38 |
Cash at Beginning of Period | 245.52 | 572.74 | 177.01 | 50.55 | 147.94 |
Cash at End of Period | 444.61 | 245.52 | 572.74 | 177.01 | 50.55 |
Diluted Net EPS | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 |
Fiscal Year End for Beam Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -189.72 | -98.67 | -132.53 | -275.32 | -179.24 |
Depreciation/Amortization & Depletion | -1.50 | -1.15 | -9.73 | -7.74 | -5.04 |
Net Change from Assets/Liabilities | -61.72 | -35.60 | -114.44 | -87.23 | -65.18 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 70.18 | 35.67 | 107.50 | 86.02 | 54.97 |
Net Cash From Operating Activities | -182.76 | -99.75 | -149.20 | -284.27 | -194.48 |
Property & Equipment | -4.40 | -2.44 | -33.73 | -30.14 | -22.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 38.43 | -51.03 | 105.57 | 3.88 | 6.17 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 34.03 | -53.46 | 71.84 | -26.26 | -16.03 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.31 | 3.07 | 279.33 | 244.99 | 207.43 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.28 | -0.18 | -2.88 | -2.25 | -1.47 |
Net Cash from Financing Activities | 3.03 | 2.90 | 276.45 | 242.74 | 205.96 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -145.70 | -150.31 | 199.09 | -67.79 | -4.56 |
Cash at Beginning of Period | 444.61 | 444.61 | 245.52 | 245.52 | 245.52 |
Cash at End of Period | 298.92 | 294.30 | 444.61 | 177.73 | 240.97 |
Diluted Net EPS | -1.11 | -1.21 | 1.91 | -1.22 | -1.08 |